US Patent

US8039009 — Modified release formulations of memantine oral dosage forms

Method of Use · Assigned to Forest Laboratories Holdings ULC · Expires 2029-03-24 · 3y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects modified release formulations of memantine oral dosage forms that sustain the release of the active agent for 4 to 24 hours.

USPTO Abstract

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-539 memantine-hydrochloride
U-1641 donepezil-hydrochloride
U-1641 donepezil-hydrochloride
U-539 memantine-hydrochloride
U-1641 donepezil-hydrochloride
U-539 memantine-hydrochloride
U-539 memantine-hydrochloride
U-1641 donepezil-hydrochloride

Patent Metadata

Patent number
US8039009
Jurisdiction
US
Classification
Method of Use
Expires
2029-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Forest Laboratories Holdings ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.